Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer

MT Newswires Live

09/19

Nuvation Bio (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.

The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.

The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.

The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.

Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.

Shares of the company were up 2.1% in recent Friday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568683442"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568683442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568683442?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568683442","market":"fut","top_or_hot":-1,"title":"Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>The company said that <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> will market Ibtrozi in Japan as part of a previously signed agreement in 2023.</p><p>The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.</p><p>The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.</p><p><a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.</p><p>Shares of the company were up 2.1% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-19 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>The company said that <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> will market Ibtrozi in Japan as part of a previously signed agreement in 2023.</p><p>The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.</p><p>The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.</p><p><a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.</p><p>Shares of the company were up 2.1% in recent Friday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568683442","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568683442","pubTimestamp":1758283319,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nuvation Bio  said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.Shares of the company were up 2.1% in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NUVB":"Nuvation Bio, Inc."},"translate_title":"Nuvation Bio的Ibtrozi获得日本批准用于晚期ROS1阳性非小细胞肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1},"content_text":"Nuvation Bio (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.Shares of the company were up 2.1% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}